Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Aeterna Zentaris Inc is a biotechnology business based in the US. Aeterna Zentaris shares (AEZS) are listed on the NASDAQ and all prices are listed in US Dollars. Aeterna Zentaris employs 12 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $0.36 |
|---|---|
| 52-week range | $0.30 - $3.62 |
| 50-day moving average | $0.42 |
| 200-day moving average | $0.69 |
| Wall St. target price | $2.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.07 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.355 from 2022-01-26
| 1 week (2022-01-16) | N/A |
|---|---|
| 1 month (2021-12-23) | -15.52% |
| 3 months (2021-10-23) | N/A |
| 6 months (2021-07-27) | -53.29% |
| 1 year (2021-01-27) | -52.67% |
|---|---|
| 2 years (2020-01-27) | -70.42% |
| 3 years (2019-01-25) | 3.63 |
| 5 years (2017-01-27) | 2.55 |
| Revenue TTM | $4.2 million |
|---|---|
| Gross profit TTM | $1.3 million |
| Return on assets TTM | -7.1% |
| Return on equity TTM | -17.3% |
| Profit margin | -156.35% |
| Book value | $0.49 |
| Market capitalisation | $42 million |
TTM: trailing 12 months
We're not expecting Aeterna Zentaris to pay a dividend over the next 12 months.
Aeterna Zentaris's shares were split on a 1:100 basis on 19 November 2015. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aeterna Zentaris shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Aeterna Zentaris shares which in turn could have impacted Aeterna Zentaris's share price.
Over the last 12 months, Aeterna Zentaris's shares have ranged in value from as little as $0.2971 up to $3.62. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeterna Zentaris's is 2.0044. This would suggest that Aeterna Zentaris's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aeterna Zentaris Inc. , a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.